Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule (Q37445501)

20 August 2017

1 reference

title

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule (English)

1 reference

20 August 2017

0 references

Orthoebolavirus zairense

0 references

Barney S Graham

1 reference

20 August 2017

Nancy J Sullivan

1 reference

20 August 2017

Julie E Martin

1 reference

20 August 2017

Gary J Nabel

series ordinal

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

Nature Reviews Microbiology

20 August 2017

published in

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

page(s)

393-400

1 reference

Ebolavirus and Marburgvirus: insight the Filoviridae family

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Vaccines: correlates of vaccine-induced immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

A framework for assessing immunological correlates of protection in vaccine trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Correlates, surrogates, and vaccines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Inflammatory responses in Ebola virus-infected patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Cytokine and chemokine expression in humans infected with Sudan Ebola virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Human asymptomatic Ebola infection and strong inflammatory response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Early immune responses accompanying human asymptomatic Ebola infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Sequence-based human leukocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Disease modeling for Ebola and Marburg viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Immunization for Ebola virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Epitopes involved in antibody-mediated protection from Ebola virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Persistent infection with ebola virus under conditions of partial immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

CD8-mediated protection against Ebola virus infection is perforin dependent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Role of natural killer cells in innate protection against lethal ebola virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Development of a preventive vaccine for Ebola virus infection in primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Successful topical respiratory tract immunization of primates against Ebola virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Development and homeostasis of T cell memory in rhesus macaque

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2129

Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19369954

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19369954

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRMICRO2129

1 reference

20 August 2017

1 reference